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ABSTRACT
Objective: Renin–angiotensin–aldosterone system (RAAS) plays an important role in regulating post-myocardial infarction (post-MI) events. Ramipril 
and losartan act mainly by inhibiting RAAS. This study was designed to compare the efficacy and safety of ramipril against losartan in post-MI patients.
Methods: A total of 100 enrolled patients were divided into two groups A and B of 50 each by computer-generated random numbers. Group A 
(n=50) patients were given ramipril 1.25–2.5 mg once a day and Group B (n=50) patients were given losartan 25–50 mg once a day. The patients 
were followed after 0, 1, and 3 months and at 6 months (optional). Efficacy was compared based on the left ventricular ejection fraction (LVEF%) 
and New York Heart Association class improvement. Safety was compared by considering ADRs, mortality, and biochemical test profile. Data were 
analyzed using unpaired t-test and Chi-square test. p<0.05 was considered to be statistically significant.
Results: The mean LVEF% at 0 month for Group A was 40.6 ± 4.48 and for Group B was 39.6 ± 4.02 (p=0.212). The mean LVEF% at 6 months for Group A 
was 45.12 ± 4.6 and for Group B was 43.57 ± 4.03 (p=0.11). The most common side effects were headache in Group A and hypotension in Group B.
Conclusion: Both ramipril and losartan are equally efficacious; however, losartan has a better safety profile than ramipril.
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INTRODUCTION
Coronary artery disease (CAD) is a major cause of death and disability 
in developed countries [1]. The 2016 Heart Disease and Stroke Statistics 
update of the American Heart Association has recently reported that 
15.5 million persons ≥20 years of age in the USA have CAD [2], and 
the overall death rate from CAD was 102.6/100,000 population [3]. In 
India, the prevalence has increased to 9%–10% in urban populations 
and 4%–6% in rural populations [4].
Post-myocardial infarction (post-MI) events such as left ventricular 
(LV) dilatation and remodeling start immediately after acute MI 
and upregulation of renin–angiotensin–aldosterone system (RAAS) 
plays an important role in the pathogenesis of LV remodeling in 
post-MI patients [5]. Successful mechanical reperfusion therapy and 
current pharmacological treatment can limit cardiac dysfunction and 
ventricular remodeling in acute MI to some extent [5]. The current 
modalities of pharmacologic treatment of post-MI are beta-blockers, 
angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin 
receptor blockers (ARBs) [6].
ACEI and ARBs are considered a breakthrough in the treatment of post-MI 
patients for reducing mortality and morbidity [7]. Numerous studies 
have been conducted in the past to compare the efficacy and safety of 
ACEIs against ARBs, but still, there is no conclusive evidence. Hence, the 
present study was designed with an aim to compare the efficacy and 
adverse reaction profile of ramipril versus losartan in post-MI patients.
MATERIALS AND METHODS
It was a prospective, open-label, comparative randomized study and was 
conducted in a total of 100 (n=100) patients. Patients were enrolled as 
per the inclusion and exclusion criteria. Patients underwent a thorough 
clinical examination including history for any ongoing disease or drug 
intake, vital signs, and systemic examination. Informed consent was 
taken from the patients.
The inclusion criteria were 7 days post-MI patients of age between 
20 and 75 years of either gender with a history of ST elevation on 
electrocardiogram and LV dysfunction with the LV ejection fraction 
(LVEF) ≤45%. Pregnant and lactating women, patients with known 
hypersensitivity to angiotensin receptor inhibitors and ARBs, known 
cases of angioedema, renal artery stenosis, aortic stenosis, hypertrophic 
cardiomyopathy, collagen vascular diseases, and renal dysfunction with 
serum creatinine >1.5 mg/dl were excluded.
After signing the written informed consent, 100 patients were enrolled. 
The enrolled patients were divided into two groups A and B by 
computer-generated random numbers. Both the groups consisted of 
50 patients each. Group A (n=50) patients were given ACEI (ramipril) 
1.25–2.5 mg once a day and Group B (n=50) patients were given ARB 
(losartan) 25–50 mg once a day. The patients were followed after 
0, 1, and 3 months, and 6 months (optional). The baseline clinical 
characteristics recorded were systolic and diastolic blood pressure 
(mmHg), heart rate per min, respiratory rate per min, and peripheral 
capillary oxygen saturation (SpO2%), at the time of enrollment for every 
patient and were reevaluated during follow-up as needed. Efficacy was 
compared based on the primary parameters and safety based on the 
secondary parameters.
Primary parameters were LVEF and New York Heart Association 
(NYHA) classification. Secondary parameters were adverse drug 
reactions (ADRs) which were spontaneously recorded; renal function 
tests which included blood urea nitrogen, serum creatinine, sodium, 
and potassium, and the number of deaths.
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Data were analyzed using unpaired t-test and Chi-square test. p<0.05 
was considered to be statistically significant.
RESULTS
The mean age of patients was 56 ± 10.89 years in Group A and 
55.92 ± 9.53 years in Group B. In Group A, there were 39 males and 
11 females and Group B also had 39 males and 11 females. The mean 
weight of patients was 63.16 ± 5.72 kg in Group A and 63.5 ± 5.78 kg in 
Group B. The demographic baseline characteristics have been shown 
in Table 1.
There was no significant difference in the demographic profile in both 
the groups (p>0.05).
The baseline clinical characteristics of patients in both the groups are 
given in Table 2.
The mean LVEF% at 0 month for Group A was 40.6 ± 4.48 and for 
Group B was 39.6 ± 4.02 (p=0.212). The mean LVEF% at 6 months for 
Group A was 45.12 ± 4.6 and for Group B was 43.57 ± 4.03 (p=0.11) 
(Table 3). The mean LVEF% was slightly higher in Group A as compared 
to Group B at baseline and 6 months; however, it was not statistically 
significant (p>0.05). There was an increasing trend in LVEF% in both 
Group A and Group B with respect to time, but the difference in LVEF% 
between the two groups at 0 and 6 months was comparable (p>0.05).
The NYHA classification of study participants in both the groups 
is depicted in Table 4. Functional outcome in both the groups was 
comparable (p>0.05). At baseline in Group A, 72% of the study participant 
was in Class 1, and in Group B, 68% of the study participant was in Class 1. 
There was no significant difference in the functional outcome in both the 
groups (p=0.663) at baseline. At 1 month, 3 months, and 6 months, all 
the study participants of both the groups were in Class 1. There was no 
significant difference in NYHA classification between the two groups.
ADR monitoring was done for both Group A and Group B (Table 5). 
There was no statistically significant difference in ADR between two 
groups (p>0.05) except headache (p<0.05). In the study Group A, 
12% of patients reported headache, whereas in the study Group B, no 
patient reported headache so the incidence of headache in the study 
Group A was significantly higher as compared to B (p=0.027). There 
was no statistically significant difference in the incidence of dry cough, 
hypotension, abnormal kidney function, and hyperkalemia between 
two groups (p>0.05). Seven patients of Group A and six patients of 
Group B left the study due to the side effects. There was mortality of 
three patients within 6 months.
DISCUSSION
In our study, the mean age of patients in both the groups was 
comparable (p>0.05) with most of them being in 51–70 years age group 
with confirmed acute MI. In the ELITE study [8], patients were 65 years 
or more, in the OPTIMAAL study [9], patients were 50 years of age or 
older (mean age 67.4 years [standard deviation 9.8]). Similar results 
were seen by Kumar et al. [10].
The sex distribution in both the groups was comparable, with 78% of 
males and 22% of females and mean weight of 63.33 ± 5.73 kg. Women 
are less susceptible to coronary heart disease and other atherosclerotic 
diseases as compared to men [11].
The baseline clinical characteristics studied were systolic and diastolic 
blood pressure (mmHg), heart rate per min, respiratory rate per min, 
and SpO2%. The difference of parameters between the two groups was 
not statistically significant in our study. Similar results were seen in 
other studies also where no difference in outcome was seen compared 
with their baseline clinical parameters. Garg and Yusuf [12] and Flather 
et al. [13] found that the benefits of treatment on all outcomes were 
independent of age, sex, and baseline use of diuretics, aspirin, and beta-
blockers.
Mean LVEF% in our study was 40.1 ± 4.26. A follow-up of 3–6 months 
was done. All the patients were in Class 1 and 2 NYHA. A stringent 
inclusion criterion of LVEF% <45 was being followed in our study. 
Other studies had slightly different criteria. Køber et al. [14], in the 
Trandolapril Cardiac Evaluation trial, randomized post-MI patients 
with an LVEF of 35% or less with a follow-up of 24–50 months. Yusuf 
et al. [15] excluded patients with an LVEF <40% or a history of chronic 
heart failure. In his study, subjects were randomized to treatment with 
ramipril or placebo for an average of 5 years. Pitt et al. [8] in the ELITE 
study compared the safety and efficacy advantages of losartan with 
captopril in the treatment of older heart failure patients. A number of 
722 ACEI-naive patients (aged 65 years or more) with NYHA Class II-IV 
heart failure and ejection fractions of 40% or less were followed for 
48 weeks. In a study by Pfeffer et al. [16], patients were randomized 
Table 1: Demographic baseline characteristics
Demographic 
characteristic
Group A (%) Group B (%) Total (%)
≤40 years 4 (8.00) 3 (6.00) 7 (7.00)
41–50 years 12 (24.00) 11 (22.00) 23 (23.00)
51–60 years 16 (32.00) 24 (48.00) 40 (40.00)
61–70 years 18 (36.00) 12 (24.00) 30 (30.00)
Mean age (y) 56±10.89 55.92±9.53 55.96±10.18
F; Female 11 (22.00) 11 (22.00) 22 (22.00)
M; Male 39 (78.00) 39 (78.00) 78 (78.00)
Mean weight (kg) 63.16±5.72 63.5±5.78 63.33±5.73
Table 2: Baseline clinical parameters of study participants
Clinical parameters Group A Group B p
SBP (mmHg) 112.48±9.46 116.8±11.81 0.097*
DBP (mmHg) 75.28±5.75 76.12±6.61 0.51*
HR/min 83.24±10.68 84.1±10.59 0.895*
Respiratory rate/min 20.72±2.17 20.64±1.48 0.616*
SpO2% 98.56±0.5 98.7±0.46 0.149*
*p>0.05. SBP: Systolic blood pressure, DBP: Diastolic blood pressure, 
HR: Heart rate
Table 3: Left ventricular ejection fraction (%) (mean±standard 
deviation) in groups at baseline and 6 months
Follow‑up interval LV%–EF% p
Group A Group B
0 month 40.6±4.48 39.6±4.02 0.212
6 months 45.12±4.6 43.57±4.03 0.11
*p<0.05 as compared to 6 months. LV: Left ventricular, EF: Ejection fraction




Group A (%) Group B (%) Total (%) p
0 month
Class 1 36 (72.00) 34 (68.00) 70 (70.00) 0.663
Class 2 14 (28.00) 16 (32.00) 30 (30.00)
1 month
Class 1 49 (100.00) 44 (100.00) 93 (100.00) -
Class 2 0 (0.00) 0 (0.00) 0 (0.00)
3 months
Class 1 41 (100.00) 42 (100.00) 83 (100.00) -
Class 2 0 (0.00) 0 (0.00) 0 (0.00)
6 months
Class 1 41 (100.00) 42 (100.00) 83 (100.00) -
Class 2 0 (0.00) 0 (0.00) 0 (0.00)
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with an LVEF ≤40% to placebo or captopril 3–16 days post-MI and were 
followed for a mean of 42 months.
Our results showed a significant improvement in LVEF% and NYHA 
class in both the groups (p<0.0001), but not significantly different from 
each other. In our study, ramipril and losartan attenuated progressive 
increases in LV dilation and hypertrophy in patients with LV dysfunction, 
irrespective of the patient’s symptomatic status.
In comparison, both the drugs were found to be equally effective. 
Hence, an efficacy advantage of either drug could not be established. 
Other studies in the past such as OPTIMAAL and VALIANT trials also 
could not establish the efficacy advantage of ARBs over ACEIs [9,16,17].
ACEIs, but not ARB, prevent bradykinin degradation and allow it to 
accumulate, leading to the known side effects of ACEI therapy such 
as cough, rash, and angioedema [18]. Thus, the most common and 
noticeable side effect of dry cough is common with ACEI therapy and 
minimal with ARBs. In our study, dry cough was seen only in patients 
treated with ramipril and not with losartan. Side effects such as a mild 
headache, hypotension, and abnormal kidney function tests were seen 
in few of the ramipril-treated patients. Other known side effects of 
ramipril such as angioedema, dizziness, nausea, vomiting, diarrhea, 
vasculitis Henoch-Schönlein purpura, vertigo, and impotence were 
not seen in our study. Losartan, the first ARB that was approved for 
clinical use, has been associated with a low incidence of cough, similar 
to that of the diuretic hydrochlorothiazide, in patients with a history 
of ACEI-induced cough [19]. Numerous comparative trials have been 
performed, demonstrating the lower incidence of cough associated 
with several ARBs compared to that with ACEIs [20]. In our study, no 
patient treated with losartan reported cough as a side effect. Side effects 
such as hypotension, abnormal kidney function tests, and hyperkalemia 
were seen in few of the losartan-treated patients. Seven patients left 
the study due to side effects of ramipril. OPTIMAAL and VALIANT trial 
showed similar results in terms of side effects and discontinuations 
from the study [9,16,17].
In our study, serum potassium, sodium, creatinine, and BUN levels were 
regularly monitored. Mild hyperkalemia was reported in few patients on 
losartan but not in ramipril group. Other biochemical parameters were 
in the control range. No alarming values were reached for any patient in 
the study. An improvement in the biochemical values was seen in both 
ramipril- and losartan-treated patients on regular follow-ups.
Due to the effects on RAAS, the use of ACEI and ARBs can be associated 
with hyperkalemia, especially in patients with chronic renal sufficiency. 
Up to 10% of the patients may experience at least hyperkalemia [20]. 
However, Hameed et al. [21] noted no side effect with losartan as 
compared to amlodipine. These ADRs can be minimized by creating 
awareness among the professionals [22].
Mortality and the number of patients leaving the study were comparable 
in both ramipril- and losartan-treated groups. There was no direct 
mortality due to side effects of drugs. Patients left the study due to 
the side effects, particularly mild headache and cough. Fewer patients 
in the losartan group (excluding those who died) discontinued study 
due to adverse effects in other studies such as ELITE II, VALIANT, and 
OPTIMAAL trials [9,16,17]. Further studies entailing long follow-up and 
more patients with a different combination of drugs may be required to 
arrive at a definitive conclusion and to know the long-term side effects 
of the drugs.
The main strengths of this study were the completeness of the 
investigations in terms of baseline and 6-month follow-up. Although 
the MI diagnosis was not validated, LVEF and NYHA class were taken 
into account. Detailed information about important risk factors such 
as smoking and obesity and family history was obtained. This study 
did analyze the efficacy and side effects of ACEIs and ARBs in the early 
treatment post-MI, contributing to the data in other different studies.
CONCLUSION
Both ramipril and losartan are equally efficacious; however, losartan 
has a better safety profile than ramipril; therefore losartan can be 
preferred in certain patients.
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